{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:19:48Z","timestamp":1790011188896,"version":"4.0.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s143008","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T03:06:11Z","timestamp":1501815971000},"page":"957-965","source":"Crossref","is-referenced-by-count":18,"title":["Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Kathleen A.","family":"Fairman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sclar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,8]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=37784","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=37784","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T03:06:12Z","timestamp":1501815972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/real-world-use-of-pcsk-9-inhibitors-by-early-adopters-cardiovascular-r-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s143008","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}